Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. [1 ]
Baum, R. P. [1 ]
机构：
[1] Ctr PET, Dept Nucl Med, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [1] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [2] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [3] Serial dosimetry during Lu-177 PSMA radioligand therapy in the same patient
    Kulkarni, Harshad
    Schuchardt, Christiane
    Singh, Aviral
    Baum, Richard
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [4] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [5] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [6] Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies
    Mair, C.
    Warwitz, B.
    Buxbaum, S.
    Virgolini, I. J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S454 - S454
  • [7] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [8] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [9] Methodological Effects in Kidney Dosimetry in Lu-177 Radionuclide Therapy
    Heikkonen, J.
    Maenpaa, H.
    Tenhunen, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S265 - S265
  • [10] LU-177 DOTATATE THERAPY IN PATIENTS WITH NETS
    Hosking, E.
    McKay, E.
    Browne, E.
    Thomas, D.
    Liauw, W.
    Morris, D.
    Chu, F.
    Hayes, A.
    Butler, P.
    [J]. INTERNAL MEDICINE JOURNAL, 2015, 45 : 18 - 18
12345